Department

 Celltrion Awarded up to $626 Million From the Department of Defense to Supply COVID-19 Point-of-Care (POC) Rapid Antigen Test Kits

White House, Federal Government, Public Policy, Government, Health, Infectious Diseases, Pharmaceutical, Biotechnology, Food, POCT, Therapy, FDA, Patient, Defense, US Foods, CEO, Antibody, EUA, Defense Logistics Agency, Two-phase electric power, COVID-19, EU, Research, Infection, Safety, DLA, Department of Defense Serum Repository, Department, Fine chemical
Thursday, September 23, 2021 - 8:00am

Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.

Key Points: 
  • Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.
  • Celltrions supply capability for the contract volume is sufficiently supported by the large-scale production facility in Korea.
  • The test kits to be supplied through this contact are point-of-care tests (POCT) which can only be used in the presence of medical professionals.
  • Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs.

VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform

World Intellectual Property Day, Vaccine, RNA, Biopharmaceutical, Pandemic, Therapy, Infection, Imperial College London, Element, Board, Death, SaRNA, Immunology, Disease, AstraZeneca, Technology, Imperial, Robin, Research, Drug discovery, Interferon, Protein, Department
Thursday, September 23, 2021 - 7:00am

LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products.

Key Points: 
  • LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products.
  • The strategic, long-term research collaboration with AstraZeneca aims to optimise and validate VaxEquity's saRNA platform and apply it to advance novel therapeutic programmes.
  • AstraZeneca will support VaxEquity with research and development funding and has the option to collaborate with VaxEquity on up to 26 drug targets.
  • Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said "This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox.

VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform

World Intellectual Property Day, Vaccine, RNA, Biopharmaceutical, Pandemic, Therapy, Infection, Imperial College London, Element, Board, Death, SaRNA, Immunology, Disease, AstraZeneca, Technology, Imperial, Robin, Research, Drug discovery, Interferon, Protein, Department
Thursday, September 23, 2021 - 7:00am

LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products. VaxEquity could receive development, approval and sales-based milestones totalling up to $195 million and royalties in the mid-single digits per drug target. VaxEquity also received an upfront equity investment from AstraZeneca and global life sciences investor Morningside Ventures.

Key Points: 
  • LONDON, Sept. 23, 2021 /PRNewswire/ -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company's platform technology through proof of concept to enable the development of multiple products.
  • The strategic, long-term research collaboration with AstraZeneca aims to optimise and validate VaxEquity's saRNA platform and apply it to advance novel therapeutic programmes.
  • AstraZeneca will support VaxEquity with research and development funding and has the option to collaborate with VaxEquity on up to 26 drug targets.
  • Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said "This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox.

ChampionX Announces Investment in PingThings, Inc.

Primary energy, Health, NASDAQ, National Science Foundation, Growth, Intelligence Advanced Research Projects Activity, Technology, GLOBE, Department, Renewable energy
Thursday, September 23, 2021 - 2:00am

"We are excited to have ChampionX involved in this funding round given their deep understanding and track record of delivering exceptional technology innovation within the energy industry.

Key Points: 
  • "We are excited to have ChampionX involved in this funding round given their deep understanding and track record of delivering exceptional technology innovation within the energy industry.
  • ChampionX is a global leader in chemistry solutions and highly engineered equipment and technologies that help companies drill for and produce oil and gas safely and efficiently around the world.
  • ChampionXs products provide efficient functioning throughout the lifecycle of a well with a focus on the production phase of wells.
  • To learn more about ChampionX, visit our website at www.championX.com .

New Hampshire Announces Formation of Collaborative Economic Development Regions

Economy, Caswell, BEA, Economic recovery, Granite State College, CEDR, Entrepreneurship, Business, Coast, COVID, Granite State, COVID-19, New Hampshire Department of Transportation, ERES, Economic development, New, Department, Management
Wednesday, September 22, 2021 - 11:40pm

CONCORD, N.H., Sept. 22, 2021 /PRNewswire-PRWeb/ -- The New Hampshire Department of Business and Economic Affairs (BEA) announced today the first of the Collaborative Economic Development Regions (CEDRs) have been established to promote economic expansion post COVID.

Key Points: 
  • CONCORD, N.H., Sept. 22, 2021 /PRNewswire-PRWeb/ -- The New Hampshire Department of Business and Economic Affairs (BEA) announced today the first of the Collaborative Economic Development Regions (CEDRs) have been established to promote economic expansion post COVID.
  • "While the pandemic has taken a significant toll on the Granite State, New Hampshire has proven resilient.
  • The new regional groups will create a mechanism to facilitate strong collaboration among economic development partners in addressing areas such as business retention and attraction; workforce development; entrepreneurship; infrastructure, and business advocacy.
  • The Department of Business and Economic Affairs is dedicated to enhancing the economic vitality of the State of New Hampshire while promoting it as a destination for domestic and international visitors.

Dr. Sarah Teichmann FmedCci FRS Joins Transition Bio as Scientific Co-Founder

Technology, Biotechnology, Nanotechnology, Health, Pharmaceutical, Oncology, Other Science, Research, Software, General Health, Genetics, Science, Data Management, Clinical Trials, Biophysics, Biochemical Society, Distinguished Fellow of the British Computer Society, Artificial intelligence, Research, Computational biology, Wellcome Sanger Institute, Harvard University, OC, EMBO, Medicine, Teichmann, Therapy, Health, Yusuf Hamied Department of Chemistry, Mallinckrodt, Map, Research fellow, Cavendish Laboratory, Physical chemistry, Academy of Medical Sciences (United Kingdom), Laboratory, Gold medal, Fellow, International Society, Biology, Drug design, Genomics, University, Royal Society, Company, EMBO Gold Medal, Disease, Technology, Algorithm, Science, FRCP, Applied physics, Royal, Churchill College, Cambridge, Drug discovery, Transition, Department, FRS, FRSC, Machine learning, Physics, Academy, Management, Pharmaceutical industry
Wednesday, September 22, 2021 - 9:30pm

Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.

Key Points: 
  • Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.
  • Dr. Samuel Cohen, a former research fellow in Biophysical Chemistry at the University of Cambridge and visiting fellow at Harvard University, is also a Founder of the Company.
  • Martin commented further, From a scientific leadership and breakthrough innovation standpoint, the combination of our scientific team of doctors Weitz, Knowles, Hyslop, and now Teichmann is as good as it could possibly get.
  • Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis.

TTUHSC El Paso's Life-Saving Cancer Prevention Programs Receive $5 Million in CPRIT Funding

Mortality, BEST, Breast, Insurance, Colorectal cancer, Texas Panhandle, Public health, Large intestine, Breast cancer, Depression, Patient, Research institute, Physician, Cancer prevention, Texas Tech University Health Sciences Center, Woman, Colorado Water Quality Control Division, Center, Disease, Department, Education, GLOBE, Cancer Prevention and Research Institute of Texas, Health insurance, Birth control
Wednesday, September 22, 2021 - 8:30pm

TTUHSC El Paso's SuCCCeS and the Breast Cancer Education, Screening and Navigation (BEST) programs screen for cancer and provide cancer-prevention education for uninsured or underinsured residents.

Key Points: 
  • TTUHSC El Paso's SuCCCeS and the Breast Cancer Education, Screening and Navigation (BEST) programs screen for cancer and provide cancer-prevention education for uninsured or underinsured residents.
  • The agency provides funding for public and private institutions of higher education and recently renewed its funding for TTUHSC El Paso's two screening programs for a total of $5 million.
  • Earlier this year, she took over as director for the Cancer Prevention and Control Division, which oversees all cancer screening programs.
  • "They see our success in El Paso and West Texas, which is a main reason why CPRIT continues funding our programs," Dr. Molokwu said.

Alight Welcomes Social Innovator, Jocelyn Wyatt, As New CEO

International development, Solution, Charity, Department for International Development, Multimedia, Population Services International, Refugee, Non-governmental organization, Bill, CEO, PSI, NGO, DFID, Creativity, Chair, Department, Organization, Bill & Melinda Gates Foundation, Management
Wednesday, September 22, 2021 - 7:47pm

MINNEAPOLIS, Sept. 22, 2021 /PRNewswire/ -- Global humanitarian organization, Alight , is pleased to announce Jocelyn Wyatt as the newly appointed CEO.

Key Points: 
  • MINNEAPOLIS, Sept. 22, 2021 /PRNewswire/ -- Global humanitarian organization, Alight , is pleased to announce Jocelyn Wyatt as the newly appointed CEO.
  • Having served as the CEO of IDEO.org for the past 10 years, Wyatt will officially take the helm of Alight on December 15, 2021, where she will lead more than 3,500 team members globally.
  • "We are exceptionally pleased to welcome such an accomplished creative strategist and highly esteemed member of the international NGO community," says Maureen Reed, Chair, Alight Board of Directors.
  • In 2020, Alight received the prestigious 4-Star Rating from Charity Navigator for the tenth consecutive year, celebrating a decade of impactful work.

Essye B. Miller joins Millennium Corporation Board of Advisors

Cloud, Policy, Joint Artificial Intelligence Center, Department of Defense Cyber Crime Center, Red team, Software engineering, Federal, Multimedia, Information management, Crystal, Board, Principal, Computer security, United States Department of Defense, Intelligence, Retirement, Engineering, COO, Industry, Central Waqf Council, Department, Management, Risk management
Wednesday, September 22, 2021 - 7:00pm

ARLINGTON, Va., Sept. 22, 2021 /PRNewswire/ -- As a new member of Millennium Corporation's Board of Advisors, Essye B. Miller will leverage her skills and industry expertise to provide strategic guidance and direction into Millennium Corporation's executive team.

Key Points: 
  • ARLINGTON, Va., Sept. 22, 2021 /PRNewswire/ -- As a new member of Millennium Corporation's Board of Advisors, Essye B. Miller will leverage her skills and industry expertise to provide strategic guidance and direction into Millennium Corporation's executive team.
  • Essye B. Miller is a recognized leader with over 35 years of Federal and Department of Defense (DoD) experience driving cross-cutting information technology and business transformation initiatives.
  • Ms. Miller served as the Principal Deputy Chief Information Officer for the Department of Defense from 2018 until her retirement in 2020.
  • Traviss Green, COO of Millennium Corporation, stated that, "We are all so excited to welcome Essye Miller to our Board of Advisors.

Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting

Linda, EMANATE, Endocrine Society, Polyphagia, ESPE, Hunger, MC4R, Weight loss, Bardet–Biedl syndrome, Exercise, BBS, Patient, Pediatrics, Pediatric endocrinology, Microdeletion syndrome, Â, SRC1, Gene, SH2B1, Chromosomal deletion syndrome, Company, European Society of Gene and Cell Therapy, Diet, Obesity, Nasdaq, GLOBE, Department, Pharmaceutical industry
Wednesday, September 22, 2021 - 3:30pm

“In addition to presenting data from our Phase 2 and 3 trials of setmelanotide, we also presented posters at ESPE describing the gene selection process and the design of our Phase 2 DAYBREAK trial,” said Linda Shapiro, M.D., Ph.D., Chief Medical Officer of Rhythm. “We are excited to share these presentations, which provide further rationale for our planned clinical development strategy. Collectively, these presentations depict setmelanotide’s potential to deliver meaningful benefit – even without change in exercise or diet -- to people with obesity and variants in the SRC1 or SH2B1 gene, both of which are included in our Phase 3 EMANATE trial, and they support our decision to enroll people with obesity and variants in at least one of 31 other genes, all of which have ‘strong’ or ‘very strong’ MC4R pathway relevance, in our Phase 2 DAYBREAK trial. We look forward to initiating both EMANATE and DAYBREAK in the fourth quarter, which will evaluate setmelanotide on top of standard of care dietary and physical activity guidance, as we work to broaden setmelanotide’s reach to many more patients with rare genetic diseases of obesity caused by variants in the MC4R pathway.”

Key Points: 
  • Together, these data support the potential for further development of setmelanotide for patients with rare genetic diseases of obesity driven by a range of variants in the MC4R pathway.
  • Rhythm also presented complete topline data from two genetic cohorts in its exploratory Phase 2 Basket Trial.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.